CDC Researchers Find New Use for Nymox's NicAlert(TM) Product.

HASBROUCK HEIGHTS, N.J. -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that researchers at the Centers for Disease Control and Prevention (CDC) reported developing a potential new use for Nymox's NicAlert(TM) product: the pre-classifying of samples prior to analysis by state-of-the-art mass spectroscopy testing (Journal of Analytical Toxicology November/December, 2005; 29: 814-818). The authors of the new NicAlert(TM) study, John T. Bernert, Tia Harmon and James McGuffey of the CDC's Tobacco Exposure Biomarkers Laboratory, coupled NicAlert(TM) testing with image scanning and processing software in order to provide more quantitative cotinine measurements in the urine of individuals exposed to second-hand smoke and tobacco products. The resulting NicAlert(TM) measurements correlated well with the far more sophisticated testing (LC/MS/MS) used in the CDC laboratory. The authors also noted this method of NicAlert(TM) testing may also be helpful in smoking cessation and other studies.

Nymox's NicAlert(TM) and TobacAlert(TM) products employ the Company's patented technology in order to provide quick, accurate, on-site measurements of cotinine levels in urine without the need for instruments or special training. Cotinine is a metabolite of nicotine that is widely accepted and used in epidemiological and medical studies for determining tobacco use and exposure. NicAlert(TM) received clearance from the U.S. FDA in October 2002 for determining smoking status for medical purposes. TobacAlert(TM) allows consumers to assess their level of second hand smoke exposure and is available at the approximately 5,400 CVS/pharmacy(R) stores across the U.S. as well as online at www.cvs.com.

Other independent peer-reviewed studies have also found the technology employed in NicAlert(TM) to be an accurate, rapid and cost-effective means of confirming smoking status in the clinic. One study, "Validating a Dipstick Method for Detecting Recent Smoking," Cancer Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125) examined the smoking status of patients at a cancer clinic and found that the results obtained using Nymox's tobacco product exposure test had an "excellent agreement" with state-of-the-art sophisticated laboratory measurements but at a substantially lower cost (over 90% less). The second study, "The Accuracy of Self-Reported Smoking Status Assessed by Cotinine Test Strips," Nicotine & Tobacco Research (2002; 4: 305-9) found Nymox's product to be "an inexpensive and rapid method to routinely biochemically confirm smoking status at a clinical visit." The authors described the Nymox product as a "simple, inexpensive and rapid measure to immediately confirm smoking status in field settings."

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.